Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Reaffirmed by HC Wainwright

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 310.24% from the stock’s previous close.

Separately, Mizuho cut their price target on shares of Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Six analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.80.

Read Our Latest Stock Report on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Stock Performance

AMLX stock traded up $0.30 during midday trading on Wednesday, reaching $1.95. 6,488,963 shares of the company’s stock traded hands, compared to its average volume of 2,431,729. The company has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $7.45. The firm has a market capitalization of $132.63 million, a PE ratio of -1.84 and a beta of -0.64. Amylyx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $25.48.

Amylyx Pharmaceuticals (NASDAQ:AMLXGet Free Report) last announced its earnings results on Friday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. The company had revenue of $88.64 million during the quarter, compared to analysts’ expectations of $113.26 million. During the same quarter last year, the firm posted $0.02 earnings per share. As a group, analysts predict that Amylyx Pharmaceuticals will post -1.36 EPS for the current fiscal year.

Institutional Trading of Amylyx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund raised its stake in shares of Amylyx Pharmaceuticals by 11.9% during the fourth quarter. New York State Common Retirement Fund now owns 23,754 shares of the company’s stock valued at $350,000 after acquiring an additional 2,519 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Amylyx Pharmaceuticals by 69.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,389 shares of the company’s stock valued at $153,000 after acquiring an additional 4,255 shares during the last quarter. Quest Partners LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at about $89,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Amylyx Pharmaceuticals by 351.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,815 shares of the company’s stock valued at $115,000 after acquiring an additional 6,085 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Amylyx Pharmaceuticals by 8.7% during the first quarter. Swiss National Bank now owns 86,600 shares of the company’s stock valued at $246,000 after acquiring an additional 6,900 shares during the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.

See Also

Analyst Recommendations for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.